Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… may leads to lower adherence to iron chelation therapy rates (n, N) compared with DFP plus deferasirox (DFX) (low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RR 0.84 [0.72, 0.99]
1 study · 96 participants
Low

DFP and DFO vs DFP and DFX

SAEs

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
1 [0.06, 16.22]
1 study · 96 participants
Very low

It is very uncertain whether summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… changes all‐cause mortality ‐ at 1 year ‐ trial end compared with DFP plus deferasirox (DFX) (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RD 0
1 study · 96 participants
Very low

DFP and DFO vs DFP and DFX

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs DFP and DFX

QoL

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
GRADE not reported

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Oral classical immunosuppressants… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral classical immunosuppressants (azathioprine, methotrexate,… (low certainty).

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
RR 1.67 [0.96, 2.88]
2 studies · 80 participants
Low

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Incidence of serious adverse events · adults with alopecia areata

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 154 participants
Very low

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Treatment of clinical and electrographic seizures vs treatment of clinical seizures alone

Seizure burden during hospitalisation · neonates

1 finding from 1 review

Anti‐seizure medications for neonates with seizures 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 68 participants
Low

Summary of findings table ‐ Treatment of clinical and electrographic seizures vs treatment of clinical seizures alone

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐seizure medications for neonates with seizures 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Treatment of clinical and electrographic seizures vs treatment of clinical seizures alone

Mortality before hospital discharge · neonates

Summary of findings table ‐ Treatment of clinical and electrographic… showed no clear difference in mortality before hospital discharge compared with treatment of clinical seizures alone (low certainty).

1 finding from 1 review

Anti‐seizure medications for neonates with seizures 2023 · Cochrane Headline outcomes only
RR 0.59 [0.28, 1.27]
2 studies · 68 participants
Low

Summary of findings table ‐ Treatment of clinical and electrographic seizures vs treatment of clinical seizures alone

Proportion of infants who develop epilepsy post‐discharge · neonates

Summary of findings table ‐ Treatment of clinical and electrographic… showed no clear difference in proportion of infants who develop epilepsy post‐discharge compared with treatment of clinical seizures alone (low certainty).

1 finding from 1 review

Anti‐seizure medications for neonates with seizures 2023 · Cochrane Headline outcomes only
RR 0.75 [0.12, 4.73]
1 study · 35 participants
Low

Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD

Treatment time (seconds) · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Very low